BCa-RCC20 is a combined uro-oncology update that builds on past years’ BCa and RCC meetings. BCa will follow RCC over the course of three days, offering delegates a chance to participate in either or both meetings. The meetings take place in Frankfurt (DE) on 26-28 June 2020 and are a collaboration between the EAU, its Oncological Urology Section (ESOU) and the European School of Urology (ESU).
Combined, BCa-RCC20 is a major three-day meeting that complements other scientific meetings that are focused on prostate cancer only. It will not only take into account the most recent scientific outcomes but also examine guideline-compliant practices through in-depth case discussions in small break-out sessions with experts. The strong educational and interactive character of the meeting sets it apart from other, larger meetings.
We spoke to Prof. Morgan Rouprêt (Paris, FR) and Prof. Axel Bex (London, GB), members of the BCa-RCC20 Steering Committee about combining the EAU’s non-prostate cancer uro-oncology meetings and some highlights for participants.
Either or both
Prof. Rouprêt explained the organisation’s shift to a combined 2020 Update after separate meetings in previous years: “It was an important decision to combine these two meetings to have a big oncology event that is not dedicated to prostate cancer. We felt that there are enough novelties, drugs in the pipeline, trials, new discoveries for bladder and renal cell cancer to have a sufficient amount of material and data to share with our colleagues in a single meeting.”
Rouprêt feels that a further advantage of combining means that BCa-RCC20 can serve as a “sister congress” to PCa20, the EAU’s Prostate Cancer Update which will take place later in the year.
Prof. Bex points out that the decision “was also driven by the fact that many urologists who do oncology are either solely treating prostate cancer, or are treating bladder and renal cancer together with other ‘smaller’ urological tumours.”
Rather than intertwining the scientific programmes with alternating cases or overlapping parallel sessions, the BCa and RCC scientific programmes follow each other over the course of the three days. Rouprêt: “We view BCa-RCC20 as one whole congress with two distinct parts. The two programmes are not running in parallel to avoid the frustration of not being able to attend both sessions.”
The two topics are strongly complementary, and in practice, urologists may be involved in both in their daily practice. “Colleagues have an ‘academic’ topic when they communicate outside their institution, but in daily practice, as onco-urologists we are all involved in the management of both diseases. Thus, it is a unique opportunity to have a broad overview of all new insights in bladder and kidney cancers in a unique event in two parts.”
Participants are encouraged to attend both meetings, requiring only one extra day of attendance and heavily discounted registration compared to paying for both meetings separately. Accommodation at the congress venue in Frankfurt is included in the registration fee for EAU Members. Special rates are also available for nurses and residents.
Scientific programme highlights
In terms of changes to the scientific programme of each meeting now that they are combined, Prof. Rouprêt emphasizes that each part has its own scientific committee. Uniquely, BCa-RCC20 has an overarching Steering Committee, of which Profs. Palou and Stenzl are members in addition to Bex and Rouprêt.
“The effect is that we came up with a unique steering committee that coordinates two distinct scientific committees. It is a unique structure for meeting organisation, much more efficient and focusing on the most important scientific aspects. From the feedback we had from former editions, we kept the popular break-out sessions to increase the interactivity between participants but we reduced as much as we could the length of plenary sessions to short and straight-to-the-point lectures to spare endless discussions about moot points.”
On Friday and early Saturday, the Renal Cell Cancer programme will be taking place. Prof. Bex is looking forward to talks on the management of the small renal masses, as well as advanced RCC where most of the new developments are occurring. “I believe we have an excellent speaker panel,” Bex says. “The advanced RCC session features presentations on the surgical and perioperative challenges of the large renal tumours (vena cava and lymph node involvement) and the perioperative care of geriatric renal tumour patients.”
On Saturday afternoon, the programme changes to bladder cancer, where there are several new developments worthy of attention. Prof. Rouprêt: “Personally, I am excited about the area of immunotherapy in localised and locally advanced disease. There is a huge opportunity for urologists to start using these drugs in their daily practice.”
“Delegates can expect some excellent presentations on the topic, including an overview of the indications for immune checkpoint inhibitors in advanced urothelial carcinoma, the role of imaging and risk stratification.”